Controversies in the Management of Community-Acquired Pneumonia

被引:0
作者
Kanal Singh
Rajasekar Jagadeesan
机构
[1] VA Northern California Health Care System,Division of Internal Medicine, Department of Veteran Affairs
关键词
Community-acquired pneumonia; Polymerase chain reaction; Procalcitonin; Empiric antibiotics; Steroids;
D O I
10.1007/s40138-016-0107-0
中图分类号
学科分类号
摘要
引用
收藏
页码:126 / 135
页数:9
相关论文
共 78 条
[1]  
Heron M(2016)Deaths: leading causes for 2013 Natl Vital Stat Rep 65 1-95
[2]  
Ramirez JA(2011)Changing needs of community-acquired pneumonia J Antimicrob Chemother 66 iii3-9-1108
[3]  
Anzueto AR(2015)Community-acquired pneumonia Lancet 386 1097-1628
[4]  
Prina E(2014)Community-acquired pneumonia N Engl J Med 371 1619-1302
[5]  
Ranzani OT(1998)Community-acquired pneumonia Lancet 352 1295-214
[6]  
Torres A(2007)An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia Infect Control Hosp Epidemiol 28 212-1444
[7]  
Musher DM(2006)Emergence of vancomycin resistant BMC Infect Dis 6 156-209
[8]  
Thorner AR(2012) (VRSA) from a tertiary care hospital from northern part of India Cochrane Database Syst Rev 41 1438-427
[9]  
Brown PD(2005)Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections Clin Infect Dis 50 202-441
[10]  
Lerner SA(2010)Impact of rapid detection of viral and atypical bacterial pathogens by real-time polymerase chain reaction for patients with lower respiratory tract infection Clin Infect Dis 373 415-18